Intellia Therapeutics’ (NTLA) “Neutral” Rating Reaffirmed at Wedbush

Intellia Therapeutics (NASDAQ:NTLA)‘s stock had its “neutral” rating reaffirmed by research analysts at Wedbush in a research report issued on Thursday,RTT News reports. They currently have a $14.00 price objective on the stock. Wedbush’s price objective indicates a potential downside of 12.50% from the stock’s current price.

NTLA has been the subject of a number of other research reports. Citigroup decreased their target price on Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Evercore ISI raised shares of Intellia Therapeutics to a “strong-buy” rating in a report on Friday, August 9th. Robert W. Baird cut their target price on shares of Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Royal Bank of Canada reiterated an “outperform” rating and set a $54.00 target price on shares of Intellia Therapeutics in a research note on Thursday, September 19th. Finally, JPMorgan Chase & Co. cut their price objective on Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 12th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Intellia Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $58.13.

Intellia Therapeutics Trading Down 0.4 %

NTLA stock traded down $0.06 during midday trading on Thursday, hitting $16.00. The company’s stock had a trading volume of 3,365,760 shares, compared to its average volume of 1,656,782. The firm’s 50-day moving average is $19.28 and its 200-day moving average is $22.25. Intellia Therapeutics has a 12 month low of $13.95 and a 12 month high of $34.87. The company has a market cap of $1.63 billion, a PE ratio of -2.92 and a beta of 1.81.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.29). The firm had revenue of $7.00 million during the quarter, compared to analysts’ expectations of $19.68 million. During the same period in the prior year, the company earned ($1.40) EPS. Intellia Therapeutics’s revenue was down 48.5% on a year-over-year basis. Analysts expect that Intellia Therapeutics will post -5.21 earnings per share for the current year.

Insider Transactions at Intellia Therapeutics

In other news, CAO Michael P. Dube sold 2,012 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total value of $38,248.12. Following the transaction, the chief accounting officer now directly owns 47,012 shares in the company, valued at $893,698.12. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 3.20% of the company’s stock.

Institutional Investors Weigh In On Intellia Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of NTLA. LMR Partners LLP increased its holdings in shares of Intellia Therapeutics by 35.3% in the third quarter. LMR Partners LLP now owns 71,100 shares of the company’s stock worth $1,461,000 after purchasing an additional 18,533 shares during the last quarter. Quest Partners LLC increased its stake in Intellia Therapeutics by 181.6% in the 3rd quarter. Quest Partners LLC now owns 19,748 shares of the company’s stock worth $406,000 after acquiring an additional 12,734 shares during the last quarter. Curi RMB Capital LLC raised its holdings in shares of Intellia Therapeutics by 13.5% during the 3rd quarter. Curi RMB Capital LLC now owns 39,187 shares of the company’s stock worth $805,000 after acquiring an additional 4,662 shares in the last quarter. KBC Group NV boosted its position in shares of Intellia Therapeutics by 37.3% during the 3rd quarter. KBC Group NV now owns 3,753 shares of the company’s stock valued at $77,000 after acquiring an additional 1,020 shares during the last quarter. Finally, Axxcess Wealth Management LLC increased its position in Intellia Therapeutics by 5.4% in the third quarter. Axxcess Wealth Management LLC now owns 20,215 shares of the company’s stock worth $415,000 after purchasing an additional 1,044 shares during the last quarter. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.